[HTML][HTML] Identification and roles of miR-29b-1-3p and miR29a-3p-regulated and non-regulated lncRNAs in endocrine-sensitive and resistant breast cancer cells
P Muluhngwi, CM Klinge - Cancers, 2021 - mdpi.com
Simple Summary Estrogen receptor α (ERα) is a key driver and clinical target in breast
cancer, with~ 75% of women having ERα+ breast tumors at diagnosis. Endocrine therapies …
cancer, with~ 75% of women having ERα+ breast tumors at diagnosis. Endocrine therapies …
Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells
P Muluhngwi, CM Klinge - Cancers, 2021 - pubmed.ncbi.nlm.nih.gov
Despite improvements in the treatment of endocrine-resistant metastatic disease using
combination therapies in patients with estrogen receptor α (ERα) primary tumors, the …
combination therapies in patients with estrogen receptor α (ERα) primary tumors, the …
[PDF][PDF] Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells
P Muluhngwi, CM Klinge - Oncol, 2019 - pdfs.semanticscholar.org
Despite improvements in the treatment of endocrine-resistant metastatic disease using
combination therapies in patients with estrogen receptor α (ERα) primary tumors, the …
combination therapies in patients with estrogen receptor α (ERα) primary tumors, the …
Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells.
P Muluhngwi, CM Klinge - Cancers, 2021 - europepmc.org
Despite improvements in the treatment of endocrine-resistant metastatic disease using
combination therapies in patients with estrogen receptor α (ERα) primary tumors, the …
combination therapies in patients with estrogen receptor α (ERα) primary tumors, the …
Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells
P Muluhngwi, CM Klinge - Cancers, 2021 - cir.nii.ac.jp
抄録< jats: p> Despite improvements in the treatment of endocrine-resistant metastatic
disease using combination therapies in patients with estrogen receptor α (ERα) primary …
disease using combination therapies in patients with estrogen receptor α (ERα) primary …
Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells.
P Muluhngwi, CM Klinge - Cancers, 2021 - search.ebscohost.com
Abstract Simple Summary: Estrogen receptor α (ERα) is a key driver and clinical target in
breast cancer, with~ 75% of women having ERα+ breast tumors at diagnosis. Endocrine …
breast cancer, with~ 75% of women having ERα+ breast tumors at diagnosis. Endocrine …
Identification and roles of mir-29b-1-3p and mir29a-3p-regulated and non-regulated lncrnas in endocrine-sensitive and resistant breast cancer cells
P Muluhngwi, CM Klinge - Cancers, 2021 - experts.umn.edu
Despite improvements in the treatment of endocrine-resistant metastatic disease using
combination therapies in patients with estrogen receptor α (ERα) primary tumors, the …
combination therapies in patients with estrogen receptor α (ERα) primary tumors, the …
[HTML][HTML] Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells
P Muluhngwi, CM Klinge - Cancers, 2021 - ncbi.nlm.nih.gov
Despite improvements in the treatment of endocrine-resistant metastatic disease using
combination therapies in patients with estrogen receptor α (ERα) primary tumors, the …
combination therapies in patients with estrogen receptor α (ERα) primary tumors, the …
Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells
P Muluhngwi, CM Klinge - Cancers, 2021 - search.proquest.com
Despite improvements in the treatment of endocrine-resistant metastatic disease using
combination therapies in patients with estrogen receptor α (ERα) primary tumors, the …
combination therapies in patients with estrogen receptor α (ERα) primary tumors, the …